Announced that it has signed a non-binding Memorandum of Understanding with Nordic Biotech Advisors. The MOU provides for Nordic Biotech II K/S or affiliates and co-investors (Nordic) to make an AU$5.2m (US$4.0m) corporate investment in pSivida and an A$28.5m (US$22.0m) investment over time in a “Special Purpose Vehicle”